Highlights Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Market Closed - Nasdaq Other stock markets 21:30:00 26/06/2024 BST			5-day change	1st Jan Change
0.537 ^USD	+6.55%		-2.75%	-49.34%

05-28	Ensysce Biosciences Back in Compliance With Nasdaq	MT
05-20	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ensysce Biosciences Back in Compliance With Nasdaq	05-28	MT
Sector Update: Health Care	05-20	MT
Ensysce Biosciences Renews Collaboration with Quotient Sciences for Pain Killer Drug Study	05-20	MT
Ensysce Biosciences, Inc. Announces Renewal of Collaboration with Quotient Sciences to Undertake the Study PF614-MPAR-102 to Examine and Evaluate the Full Commercial Dose Range of the PF614-MPAR Drug Product	05-20	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	02-21	CI
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	02-15	CI
Ensysce Shares Rally After FDA Feedback on Pain Medication	01-31	DJ
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	01-31	CI
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR	01-23	DJ
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	12-14	CI
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	11-28	CI
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study	11-16	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study	26/09/23	CI
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies	14/09/23	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol	08/08/23	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Highlights

Filters